Tower Research Capital (TRC)’s Generate Biomedicines GENB Stock Holding History

Tower Research Capital (TRC)’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12	Buy	+1	New	+$12	﹤0.01%	5069

Other funds holding GENB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Tower Research Capital (TRC)'s GENB Position: Q1 2026 in Review

Tower Research Capital (TRC) opened a new position in Generate Biomedicines (GENB) in Q1 2026: 1 share worth $12. The stake represents ﹤0.01% of the portfolio and ranks #5069 among its holdings.

57 funds tracked by Wall St. Rank hold GENB as of Q1 2026.

Tower Research Capital (TRC) held 1 share of Generate Biomedicines worth $12 as of Q1 2026.
Generate Biomedicines was a new Tower Research Capital (TRC) position in Q1 2026.
Generate Biomedicines made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #5069 holding.
57 funds tracked by Wall St. Rank held Generate Biomedicines as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.